Clinical Trial Update: Study to Determine the Effect of 14 Days Dosing With Darapladib (SB-480848) on Carotid Plague Composition in Patients With Planned Carotid Endarterectomy [Phase 2]

View source ↗

Summary

Phase 2 trial assessing 14 days of darapladib on carotid plaque composition in patients with atherosclerosis undergoing carotid endarterectomy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis

Drugs mentioned

• Darapladib (darapladib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Atherosclerosis | Phase 2 | Status: COMPLETED